Human medicines European public assessment report (EPAR): Afqlir, aflibercept, Date of authorisation: 13/11/2024, Revision: 7, Status: Authorised
What is established Afqlir is an authorised biological medicine approved in the European Union on November 13, 2024, for the treatment of several serious eye conditions, including wet age-related macular degeneration (AMD), macular oedema related to retinal vein occlusion and diabetes, and myopic choroidal neovascularisation. It is a biosimilar to the previously…
Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 13, Status: Authorised
What is established Prevenar 20 is a pneumococcal polysaccharide conjugate vaccine authorized for use within the European Union. It targets 20 serotypes of the bacterium Streptococcus pneumoniae, which can cause diseases such as pneumonia, invasive pneumococcal disease, and acute otitis media, particularly in infants from six weeks of age, children, adolescents, and…
The idea of a university
What is established Higher education in the United States has traditionally aimed to combine intellectual development with character formation, preparing students not only for careers but also for active, responsible citizenship. This dual mission has been articulated since at least the mid-20th century, notably by Martin Luther King Jr., who emphasized education’s…
Human medicines European public assessment report (EPAR): Spectrila, asparaginase, Date of authorisation: 14/01/2016, Revision: 7, Status: Authorised
Evidence Dossier: Spectrila (asparaginase) for Acute Lymphoblastic Leukaemia What is established Spectrila is a medicinal product authorized by the European Commission for use in the European Union since January 14, 2016. It contains asparaginase as its active substance and is used as part of combination chemotherapy to treat acute lymphoblastic leukaemia (ALL)…
Terms of reference for the European Sales and Use of Antimicrobials for veterinary medicine (ESUAvet) network
Health & Science Evidence Dossier: European Sales and Use of Antimicrobials for Veterinary Medicine (ESUAvet) Network What is established The European Medicines Agency (EMA) has established the ESUAvet network to monitor the sales and use of antimicrobials in veterinary medicine across Europe. This initiative aligns with ongoing efforts to combat antimicrobial resistance…
Kazakh President’s Grandnephew Donates Sport University to State Following Investigative Report
Kazakh President’s Grandnephew Donates Sport University to State Following Investigative Report This dossier examines reporting by Radio Azattyq and the Organized Crime and Corruption Reporting Project (OCCRP) on a recent development in Kazakhstan’s education sector involving Nurassyl Medeu, the grandnephew of Kazakh President Kassym-Jomart Tokayev. The matter concerns the transfer of ownership…
Human medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: Opinion
Human Medicines European Public Assessment Report (EPAR): Foundayo (Orforglipron) – Status: Opinion What is Established On 15 October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the marketing authorization of a new medicine named Foundayo. The active ingredient of Foundayo is…
Human medicines European public assessment report (EPAR): Yuviwel, Navepegritide, Status: Opinion
New Medicine Yuviwel for Achondroplasia: An Evidence Dossier What is established Yuviwel is a newly developed medicine containing the active substance navepegritide, a prodrug form of C-type natriuretic peptide (CNP). It is intended for the treatment of achondroplasia in children aged two years and older whose growth plates (epiphyses) have not yet…
Human medicines European public assessment report (EPAR): Iressa, gefitinib, Date of authorisation: 24/06/2009, Revision: 16, Status: Authorised
What is established Iressa is a medicine whose active ingredient is gefitinib, primarily used to treat adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that harbors activating mutations in the epidermal growth factor receptor (EGFR) gene. It is administered orally, typically one 250 mg tablet once daily, and can be…
Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised
What is established Vizimpro (active substance: dacomitinib) is a medicine approved in the European Union for the treatment of adults with advanced or metastatic non-small cell lung cancer (NSCLC) who have specific mutations in the epidermal growth factor receptor (EGFR) gene. It is classified as a tyrosine kinase inhibitor (TKI) that blocks…